skip navigation links
National Cancer Institute
Enterprise Vocabulary Services
Box
NCIm Version: 201808 (Browser Version 2.9, using LexEVS 6.5.1)
SearchBox Top
SearchBox Bottom
Neuroleptic Malignant Syndrome (CUI C0027849) Suggest changes to this concept
Add to Cart

Terms & Properties

Concept Unique Identifier (CUI): C0027849

NCI Thesaurus Code: C94829  (see NCI Thesaurus info)

Semantic Type: Disease or Syndrome

NCIt Definition: A rare, life-threatening disorder that is caused by neuroleptic medications. It is characterized by fever, muscular cramps and rigidity, autonomic nervous system dysfunction, and changes in the mental status that may lead to coma.

NCI-GLOSS Definition: A life-threatening condition that may be caused by certain drugs used to treat mental illness, nausea, or vomiting. Symptoms include high fever, sweating, unstable blood pressure, confusion, and stiffness.

MSH Definition: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Synonyms & Abbreviations: (see Synonym Details)
Malignant neuroleptic syndrome
Neuroleptic malgnt synd
Neuroleptic malignant syndrome (disorder)
Neuroleptic Malignant Syndrome [Disease/Finding]
Neuroleptic Malignant Syndromes
NEUROLEPTIC MALIGNANT SYNDROME
Neuroleptic malignant
NMS (Neuroleptic Malignant Syndrome)
NMS - Neuroleptic malignant syndrome
NMSs (Neuroleptic Malignant Syndrome)
NMS
Syndrome, Neuroleptic Malignant
Syndromes, Neuroleptic Malignant

External Source Codes: 
NCI Thesaurus Code C94829 (see NCI Thesaurus info)

Other Properties: Property Definitions
Name Value Source
ACTIVE 1 SNOMEDCT_US
AN caused by tranquilizing agents so do not use /chem ind MSH
AQL BL CF CL CN CO DG DH DI DT EC EH EM EN EP ET GE HI IM ME MI MO NU PA PC PP PS PX RH RT SU TH UR VE VI MSH
CASE_SIGNIFICANCE_ID 900000000000017005 SNOMEDCT_US
CASE_SIGNIFICANCE_ID 900000000000448009 SNOMEDCT_US
CHARACTERISTIC_TYPE_ID 900000000000011006 SNOMEDCT_US
CTV3ID X003d SNOMEDCT_US
DC 1 MSH
DEFINITION_STATUS_ID 900000000000074008 SNOMEDCT_US
DX 19860101 MSH
EFFECTIVE_TIME 20020131 SNOMEDCT_US
EXCLUDES1 neuroleptic induced parkinsonism (G21.11) ICD10CM
HAS_GARD_PAGE true GARD
HN 1986(1985) MSH
IAN DEFAULT ICD10
ICA Use additional E code to identify drug ICD9CM
IS_RARE true GARD
IS_SPANISH false GARD
MDA 19840605 MSH
MESH_DEFINITION A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72) NDFRT
MESH_DUI D009459 NDFRT
MESH_NAME Neuroleptic Malignant Syndrome NDFRT
MESH_UI M0014713 NDFRT
MMR 20100625 MSH
MN C10.228.140.079.737 MSH
MN C10.720.737 MSH
MN C25.723.705.600 MSH
MODIFIER_ID 900000000000451002 SNOMEDCT_US
NDFRT_KIND DISEASE_KIND NDFRT
NUI N0000002172 NDFRT
ORDER_NO 05823 ICD10CM
PM 1986; see BASAL GANGLIA DISEASES 1985 MSH
PRIMARY_PATH 10029282$10028342$10029317$10029205$Neuroleptic malignant syndrome$Muscle tone abnormal$Neuromuscular disorders$Nervous system disorders MDR
PRIMARY_SOC 10029205 MDR
PT_IN_VERSION 10.0 MDR
PT_IN_VERSION 10.1 MDR
PT_IN_VERSION 11.0 MDR
PT_IN_VERSION 11.1 MDR
PT_IN_VERSION 12.0 MDR
PT_IN_VERSION 12.1 MDR
PT_IN_VERSION 13.0 MDR
PT_IN_VERSION 13.1 MDR
PT_IN_VERSION 14.0 MDR
PT_IN_VERSION 14.1 MDR
PT_IN_VERSION 15.0 MDR
PT_IN_VERSION 15.1 MDR
PT_IN_VERSION 16.0 MDR
PT_IN_VERSION 16.1 MDR
PT_IN_VERSION 17.0 MDR
PT_IN_VERSION 17.1 MDR
PT_IN_VERSION 18.0 MDR
PT_IN_VERSION 18.1 MDR
PT_IN_VERSION 19.0 MDR
PT_IN_VERSION 19.1 MDR
PT_IN_VERSION 20.0 MDR
PT_IN_VERSION 20.1 MDR
PT_IN_VERSION 8.0 MDR
PT_IN_VERSION 8.1 MDR
PT_IN_VERSION 9.0 MDR
PT_IN_VERSION 9.1 MDR
RARE_DISEASE_URL http://rarediseases.info.nih.gov/gard/7195/neuroleptic-malignant-syndrome/resources/1 GARD
RXAUI 3203618 RXNORM
RXAUI 3206275 RXNORM
RXAUI 3206276 RXNORM
RXCUI 1021760 RXNORM
SMQ_TERM_ADDVERSION 9.0 MDR
SMQ_TERM_CAT A MDR
SMQ_TERM_LEVEL 4 MDR
SMQ_TERM_LEVEL 5 MDR
SMQ_TERM_LMVERSION 9.0 MDR
SMQ_TERM_SCOPE 2 MDR
SMQ_TERM_STATUS A MDR
SMQ_TERM_WEIGHT 0 MDR
SNOMED_CID 15244003 NDFRT
SOS Excludes: neuroleptic induced Parkinsonism (332.1) ICD9CM
SUBSET_MEMBER 447562003~CORRELATIONID~447561005 SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPADVICE~ALWAYS G21.0 | POSSIBLE REQUIREMENT FOR AN EXTERNAL CAUSE CODE SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPCATEGORYID~447637006 SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPGROUP~1 SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPPRIORITY~1 SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPRULE~TRUE SNOMEDCT_US
SUBSET_MEMBER 447562003~MAPTARGET~G21.0 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~CORRELATIONID~447561005 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPADVICE~ALWAYS G21.0 | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPADVICE~ALWAYS T43.505? | CONSIDER ADDITIONAL CODE TO IDENTIFY SPECIFIC CONDITION OR DISEASE | EPISODE OF CARE INFORMATION NEEDED | POSSIBLE REQUIREMENT FOR AN EXTERNAL CAUSE CODE SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPCATEGORYID~447637006 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPGROUP~1 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPGROUP~2 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPPRIORITY~1 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPRULE~TRUE SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPTARGET~G21.0 SNOMEDCT_US
SUBSET_MEMBER 6011000124106~MAPTARGET~T43.505? SNOMEDCT_US
SUBSET_MEMBER 900000000000497000~MAPTARGET~X003d SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000508004~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000548007 SNOMEDCT_US
SUBSET_MEMBER 900000000000509007~ACCEPTABILITYID~900000000000549004 SNOMEDCT_US
TERMUI T028186 MSH
TERMUI T364407 MSH
TH NLM (1985) MSH
TH NLM (2000) MSH
TYPE_ID 900000000000003001 SNOMEDCT_US
TYPE_ID 900000000000013009 SNOMEDCT_US
USE_ADDITIONAL code for adverse effect, if applicable, to identify drug (T43.3X5, T43.4X5, T43.505, T43.595) ICD10CM

Additional Concept Data:  (none)

URL to Bookmark: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C0027849

Mainbox Bottom